Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema

• Status: Unknown status
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the morphological and visual acuity outcomes associated with 1.5 mg bevacizumab versus 0.5 ranibizumab intravitreal injections for treatment of diabetic macular edema.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Sao Paulo
• Collaborator: Fundação de Amparo à Pesquisa do Estado de São Paulo
• Treatments: Bevacizumab; Ranibizumab

Criteria

Inclusion Criteria:

• Center-involving Diabetic macular edema unresponsive to LASER therapy performed at least 3 moths prior to inclusion;

• Best corrected visual acuity equal or worse than 20/40 and better than 20/800;

• Central subfield macular thickness greater than 300 µm

Exclusion Criteria:

• Aphakia

• High-risk proliferative diabetic retinopathy

• Previous treatment for DME in the past three months